Seres Therapeutics (NASDAQ:MCRB) Rating Reiterated by Chardan Capital

Chardan Capital reiterated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a $1.25 price objective on the biotechnology company’s stock. Chardan Capital also issued estimates for Seres Therapeutics’ FY2025 earnings at ($0.82) EPS.

Several other brokerages have also issued reports on MCRB. StockNews.com lowered shares of Seres Therapeutics from a hold rating to a sell rating in a research report on Tuesday, August 13th. Oppenheimer reissued a market perform rating on shares of Seres Therapeutics in a research report on Friday, June 7th. Finally, Canaccord Genuity Group decreased their target price on Seres Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a report on Friday, June 7th.

Seres Therapeutics Stock Down 0.6 %

MCRB opened at $0.88 on Wednesday. The stock has a market capitalization of $133.24 million, a price-to-earnings ratio of -1.47 and a beta of 1.97. The firm has a 50 day moving average price of $0.97 and a 200-day moving average price of $0.94. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $3.67.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. During the same period in the previous year, the company earned $0.36 earnings per share. As a group, analysts expect that Seres Therapeutics will post -1.03 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Teresa L. Young sold 24,480 shares of the firm’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $1.08, for a total transaction of $26,438.40. Following the sale, the insider now directly owns 78,178 shares in the company, valued at approximately $84,432.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Seres Therapeutics

Several large investors have recently made changes to their positions in MCRB. Mirae Asset Global Investments Co. Ltd. bought a new stake in Seres Therapeutics during the 1st quarter valued at approximately $39,000. Tower Research Capital LLC TRC lifted its stake in Seres Therapeutics by 668.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 33,135 shares in the last quarter. Providence Wealth Advisors LLC grew its position in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 25,250 shares in the last quarter. Point72 DIFC Ltd bought a new stake in shares of Seres Therapeutics in the second quarter worth about $64,000. Finally, Virtu Financial LLC purchased a new stake in shares of Seres Therapeutics in the first quarter worth about $73,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.